Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MEXATE-AQ vs COLUMVI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, which is required for the synthesis of purines and pyrimidines. This leads to inhibition of DNA, RNA, and protein synthesis, particularly in rapidly dividing cells. It also has immunosuppressive effects via inhibition of T cell activation and reduction of inflammatory cytokines.
CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.
FDA-approved: Chemotherapy for gestational choriocarcinoma, chorioadenoma destruens, hydatidiform mole, acute lymphocytic leukemia, meningeal leukemia, breast cancer, head and neck cancer, cutaneous T-cell lymphoma, lung cancer, non-Hodgkin's lymphoma, osteosarcoma, and mycosis fungoides.,FDA-approved: Severe, active rheumatoid arthritis (RA) in adults who have failed first-line therapy.,FDA-approved: Pediatric patients with polyarticular juvenile idiopathic arthritis (p JIA) who have failed first-line therapy.,FDA-approved: Psoriasis (severe, recalcitrant) in adults.,Off-label: Prevention of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation.,Off-label: Crohn's disease (maintenance of remission in steroid-dependent patients).,Off-label: Ectopic pregnancy (medical management).
Relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy,Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy
Methotrexate: 7.5-25 mg orally once weekly for rheumatoid arthritis; 30-40 mg/m2 IV weekly for mycosis fungoides; 50-75 mg/m2 IV over 4-6 hours weekly for osteosarcoma; 15-20 mg/m2 IM weekly for psoriasis.
12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.
Terminal elimination half-life is approximately 3–10 hours for low doses (<30 mg/m²) and 8–15 hours for high doses (>80 mg/m²). Prolonged to 48–72 hours in patients with third-space effusions or renal impairment.
Terminal half-life approximately 20 days (range 14-28 days), consistent with Ig G1 monoclonal antibody clearance via intracellular catabolism.
Metabolized primarily in the liver to polyglutamates (which are active metabolites) via folylpolyglutamate synthetase. Partial metabolism via aldehyde oxidase and xanthine oxidase to 7-hydroxymethotrexate. Methotrexate is also partially metabolized by intestinal flora. Elimination is primarily renal via glomerular filtration and active tubular secretion.
Metabolized via non-specific proteolysis into small peptides and amino acids; not metabolized by CYP450 enzymes.
Renal excretion predominates (80-90% as unchanged drug) via glomerular filtration and active tubular secretion. Biliary/fecal elimination is minor (<10%).
Primarily eliminated via biliary/fecal route; renal excretion is minimal (less than 1% of dose).
Approximately 50–60% bound primarily to albumin. Weakly bound and readily displaceable by other drugs.
No specific protein binding data; as a monoclonal antibody, it is not bound to plasma proteins in a significant manner.
Vd: 0.4–0.8 L/kg (initial 0.18 L/kg, steady-state 0.4–0.8 L/kg). Distributes into third-space fluids (pleural, ascitic), leading to prolonged elimination.
Approximately 4.5 L (0.06 L/kg assuming 70 kg), indicating limited extravascular distribution, primarily confined to plasma and interstitial space.
Oral: 30–60% (dose-dependent; saturable absorption at high doses). Intramuscular: 80–100%. Subcutaneous: approximately 90%.
Intravenous administration yields 100% bioavailability.
For GFR 40-59 m L/min: reduce dose by 20%; GFR 20-39 m L/min: reduce dose by 40%; GFR <20 m L/min: contraindicated.
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or on dialysis.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
For acute lymphoblastic leukemia (ALL): 15-20 mg/m2 IM once weekly as maintenance; for osteosarcoma: 12 g/m2 IV over 4 hours with leucovorin rescue.
Safety and effectiveness in pediatric patients have not been established.
Start at lowest recommended dose (e.g., 5 mg orally once weekly) with careful monitoring for renal function, hepatic function, and folate levels; adjust based on tolerance.
No specific dose adjustment recommended for elderly patients (≥65 years). Clinical studies included patients up to 88 years; no overall differences in safety or efficacy observed.
Boxed Warning: Methotrexate can cause fetal death or teratogenic effects when administered to pregnant women. It is contraindicated in pregnant women with psoriasis or RA. It also has a boxed warning for severe toxicity and death due to inadvertent daily (as opposed to weekly) dosing; hepatic toxicity, including acute hepatitis and chronic hepatic fibrosis; myelosuppression, including severe bone marrow suppression; and pulmonary toxicity, including acute or chronic interstitial pneumonitis. Additionally, anaphylactic reactions can occur. For patients with psoriasis, methotrexate should be used only for severe, recalcitrant cases unresponsive to other therapy.
WARNING: CYTOKINE RELEASE SYNDROME (CRS). Serious or life-threatening CRS can occur, including infusion-related reactions. Premedicate and monitor during infusion. Withhold or permanently discontinue as recommended.
Fatal toxicities (including hematologic, hepatic, pulmonary, renal, dermatologic, and GI) can occur with methotrexate; monitor closely.,Hepatic toxicity: Monitor liver function tests; avoid or use with caution in patients with active liver disease or alcohol abuse.,Pulmonary toxicity: Acute or chronic interstitial pneumonitis may occur; monitor for cough, fever, dyspnea, and hypoxia.,Myelosuppression: Monitor CBC and platelet counts regularly; severe pancytopenia can occur.,Renal toxicity: Adequate renal function is essential; avoid NSAIDs, salicylates, and other nephrotoxic drugs if possible.,Gastrointestinal toxicity: Mucositis, ulcerative stomatitis, diarrhea, and hemorrhagic enteritis may occur.,Dermatologic toxicity: Phototoxicity, radiation recall, and severe skin reactions (including Stevens-Johnson syndrome) can occur.,Immunosuppression: Increased risk of infections, including opportunistic infections; avoid live vaccines.,Carcinogenicity: Increased risk of lymphoproliferative disorders (may be reversible with discontinuation).,Concomitant use with proton pump inhibitors (PPIs) may increase methotrexate levels.
Cytokine release syndrome (CRS), including serious or life-threatening reactions,Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS),Infections, including serious and opportunistic infections,Tumor flare reaction,Embryo-fetal toxicity
Hypersensitivity to methotrexate or any component of the formulation.,Pregnancy and breastfeeding (due to risk of fetal death/teratogenicity and excretion in breast milk).,Patients with psoriasis or RA who have alcoholism, alcoholic liver disease, chronic liver disease, or overt immunodeficiency.,Pre-existing blood dyscrasias (severe anemia, leukopenia, neutropenia, thrombocytopenia).,Concomitant use with live vaccines.
None known.
Avoid folic acid-rich foods (leafy greens, fortified grains) in large amounts during methotrexate therapy as they may reduce efficacy. No specific food-drug interactions; maintain a well-balanced diet.
Avoid grapefruit and grapefruit juice. No other specific food interactions reported. Maintain adequate hydration to prevent tumor lysis syndrome.
FDA Pregnancy Category X. First trimester: High risk of miscarriage, CNS defects, craniofacial anomalies. Second trimester: IUGR, skeletal abnormalities. Third trimester: Neonatal bone marrow suppression, immunosuppression.
COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. Ig G molecules cross the placenta; fetal exposure increases as pregnancy progresses, with the largest amount transferred during the third trimester. Glofitamab may cause fetal B-cell depletion and immune dysfunction. There are no adequate human data. Contraindicated during pregnancy; advise effective contraception during treatment and for 3 months after the last dose.
Contraindicated. Methotrexate is excreted in breast milk; accumulation may occur in nursing infants due to immature renal function. M/P ratio not established; theoretical risk of serious adverse effects.
No data on presence in human milk, effects on the breastfed child, or milk production. Human Ig G is secreted into breast milk, but minimal systemic absorption in the infant is expected. Because of potential for serious adverse reactions (including B-cell depletion), advise patients not to breastfeed during treatment and for at least 3 months after the last dose. M/P ratio: unknown.
Contraindicated in pregnancy; no dose adjustment recommended due to teratogenicity. In lactating females, discontinue breastfeeding or avoid use.
No clinical trials have evaluated dosing in pregnancy. Pharmacokinetics of therapeutic antibodies are not significantly altered by pregnancy-mediated changes; however, increased plasma volume and altered clearance may occur. No specific dose adjustments are recommended; if benefit outweighs risk, administer at standard dosing (2.5 mg and 10 mg step-up doses, then 30 mg fixed dose every 21 days for up to 12 cycles). Clinical judgment required due to lack of data; consider therapeutic drug monitoring if available.
Mexate-AQ (methotrexate) requires folic acid supplementation to reduce gastrointestinal and hematologic toxicity. Administer leucovorin rescue after high-dose therapy. Avoid NSAIDs, salicylates, and sulfonamides due to increased methotrexate toxicity. Monitor renal function, liver enzymes, and blood counts regularly. Contraindicated in pregnancy, breastfeeding, and active infections.
COLUMVI (glofitamab) is a CD3x CD20 bispecific antibody for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Administer with prior rituximab and premedication to mitigate cytokine release syndrome (CRS). Monitor for CRS closely during step-up dosing; consider tocilizumab for management. Ensure adequate IV hydration and uric acid monitoring for tumor lysis syndrome. Do not coadminister with other systemic immunosuppressants unless necessary. Assess for hepatitis B reactivation prior to initiation.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid alcohol completely while on this medication.,Report any signs of infection (fever, sore throat), unusual bleeding, or mouth ulcers immediately.,Use effective contraception during treatment and for at least 3 months after stopping.,Do not take any over-the-counter medications, especially NSAIDs (ibuprofen, naproxen), without permission.,Drink plenty of fluids to prevent kidney damage.,Attend all scheduled blood tests and appointments.,Capsules should be swallowed whole; do not crush or chew.
COLUMVI is an infusion that helps your immune system attack lymphoma cells.,You will receive a low first dose and gradually higher doses to reduce side effects like fever and chills.,Common side effects include infusion reactions, tiredness, and low blood counts. Report fever, chills, or trouble breathing immediately.,Avoid grapefruit or grapefruit juice during treatment as they may affect how the medication works.,Stay well hydrated and contact your doctor if you have signs of infection or bleeding.,Do not receive live vaccines during treatment and for at least 6 months after the last dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MEXATE-AQ vs COLUMVI, answered by our medical review team.
MEXATE-AQ is a Antineoplastic Agent that works by Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, which is required for the synthesis of purines and pyrimidines. This leads to inhibition of DNA, RNA, and protein synthesis, particularly in rapidly dividing cells. It also has immunosuppressive effects via inhibition of T cell activation and reduction of inflammatory cytokines.. COLUMVI is a Antineoplastic Agent (Monoclonal Antibody) that works by CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MEXATE-AQ and COLUMVI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MEXATE-AQ is: Methotrexate: 7.5-25 mg orally once weekly for rheumatoid arthritis; 30-40 mg/m2 IV weekly for mycosis fungoides; 50-75 mg/m2 IV over 4-6 hours weekly for osteosarcoma; 15-20 mg/m2 IM weekly for psoriasis.. The standard adult dose of COLUMVI is: 12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MEXATE-AQ and COLUMVI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MEXATE-AQ is classified as Category C. FDA Pregnancy Category X. First trimester: High risk of miscarriage, CNS defects, craniofacial anomalies. Second trimester: IUGR, skeletal abnormalities. Third trimester: Neonatal . COLUMVI is classified as Category C. COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. IgG molecules cross the placenta; . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.